If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Mometasone Furoate Triumphs Over Beclomethasone Dipropionate in Patients With Mild Asthma: Presented at ACAAI By Micheal Casasnovas MIAMI BEACH, Fla -- November 10, 2009 -- Asthma therapy utilising mometasone furoate dry powder inhaler appears to better control mild asthma than beclomethasone dipropionate aerosol inhaler with hydrofluoroalkane propellant, researchers said here at the American College of Allergy, Asthma & Immunology (ACAAI) annual scientific meeting. “When compared to beclomethasone dipropionate aerosol inhaler with hydrofluoroalkane propellant patients, mometasone furoate dry powder inhaler patients experienced a longer time to any type of asthma exacerbation and a longer time to an exacerbation requiring hospitalisation,” Prakash Navaratnam, PhD, Eympres Research LLC, Columbus, Ohio, said in his poster presentation on November 8. Dr. Navaratnam and his colleagues accessed an insurance claims database to analyse outcomes among patients aged 12 to 65 years, with mild asthma. The analysis was limited to individuals who, aside from a diagnosis of asthma, did not have any chronic pulmonary condition. The researchers identified patients who had been prescribed either beclomethasone dipropionate aerosol inhaler with hydrofluoroalkane propellant or mometasone furoate dry powder inhaler between January 1, 2005, and June 30, 2008. The analysis was limited to patients who were enrolled in their health plan for at least 1 year before and after the date of their first prescription. Researchers identified 1,273 patients for each matched group. Patients using the mometasone furoate dry powder inhaler experienced significantly fewer overall exacerbation events than patients who were using the beclomethasone dipropionate aerosol inhaler with hydrofluoroalkane propellant. The event rate was 0.12 per year among those patients using the mometasone furoate dry powder inhaler compared with 0.16 events per year among those using the beclomethasone dipropionate aerosol inhaler with hydrofluoroalkane propellant (P = .0002). The analyses also illustrated that patients using the mometasone furoate dry powder inhaler had a longer time to any asthma exacerbation, with a reduced risk of 23% (P = .0414) and a longer time to asthma exacerbations requiring inpatient hospitalisation (P = .0191) compared with patients using beclomethasone dipropionate aerosol inhaler with hydrofluoroalkane propellant. “This may indicate that mometasone furoate dry powder inhaler is more effective than beclomethasone dipropionate aerosol inhaler with hydrofluoroalkane propellant in averting this potentially severe and costly exacerbation subtype,” said Dr. Navaratnam. The study was funded by Schering-Plough Corporation. [Presentation Title: Treatment With Mometasone Furoate Leads to Fewer Asthma Exacerbations and Fewer Exacerbations Requiring Inpatient Hospitalization When Compared to Beclomethasone Dipropionate in Mild Asthmatic Patients. Abstract P102]
|
